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Matrix metalloproteinases (MMPs) are a family of endoproteaseses that have various functions 
from development to disease.  They are also believed to play critical roles in the central nerve 
system for the pathogenesis of stroke.  In ischemic stroke, MMP 9 is involved in neuronal 
apoptosis, edema, and hemorrhagic transformation. In stroke models, MMPs degrade ECM 
components and disrupt neurovascular integrity, resulting in blood-brain barrier (BBB) 
disruption and hemorrhage which further damage to the ischemic area. 
There are experimental pharmacological treatments with MMP inhibitors that decrease the 
extent of neuronal apoptosis and hemorrhage.  Recently we tested a new class of mechanism-
based MMP-9 specific inhibitors SB-3CT.  Our hypothesis is that MMP-9 causes proteolytic 
changes resulting in neurovascular damage after focal cerebral ischemia in mice. Inhibition of 
MMP proteolysis with SB-3CT, should result in decreased apoptosis of neurons and improved 
behavioral outcomes. 
In two stroke paradigms in mice, we examined MMP-9 proteolysis of ECM components and 
the neuroprotective effects of the highly selective inhibitor, SB-3CT.  SB-3CT dramatically 
blocks MMP-9 activity and decreases MMP-9-mediated laminin cleavage, rescuing neurons 
from apoptosis and ameliorating neurobehavioral outcomes. Treatment with SB-3CT attenuates 
brain MMP-9 activity and protects against delayed neuronal cell death in the embolus-induced 
permanent MCAo in mice. We conclude that MMP-9 is a highly promising drug target and that 
the mechanism-based MMP-9 inhibitors have significant therapeutic potential in stroke patients.
